Recent Updates
Recently added Catalysts
NPCE Positive Sentiment

NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference

Key Takeaway: NeuroPace, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The management team will discuss their innovative RNS System, designed to improve the treatment of epilepsy. The presentation will be available via live webcast and will include investor meetings.
Price reaction · baseline $15.47 (2025-12-30 close) · hit pre-market · clean, no other NPCE news in the window
day 0 close · peak
-0.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • NeuroPace is focused on transforming the lives of epilepsy patients.
  • The company will present at a major healthcare conference.
  • The RNS System offers a novel approach to treating seizures.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~39 mo
Minimal dilution risk
Lead asset
external Responsive Neurostimulator System
Phase 2 · Epilepsy

Full Press Release Details

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 44th Annual J.P. Morgan Healthcare Conference at 3:00pm PT on Wednesday, January 14, 2026, in San Francisco, CA. Management will also host investor meetings during the conference.
The presentation will be accessible via live webcasthere. A webcast replay will be available for thirty days following the presentation in the Events & Presentations section of NeuroPace’s Investor website athttps://investors.neuropace.com.

About NeuroPace, Inc.

Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Frequently Asked Questions

When will NeuroPace present at the conference?

NeuroPace will present on January 14, 2026, at 3:00pm PT.

What is the focus of NeuroPace?

NeuroPace focuses on transforming the lives of people living with epilepsy.

How can I access the presentation?

The presentation will be available via live webcast on NeuroPace's investor website.

What is the RNS System?

The RNS System is a brain-responsive platform for treating drug-resistant epilepsy.

Last updated: Dec 31, 2025